We recently performed a study to characterize several commercially available biologic medical products. Due to budget constraints, given the very expensive nature of the products, we elected to characterize more products (to ensure characterization of a better range of what is commercially available) rather than biological replicates of just one or two of the products. Has anyone else conducted studies where biological replicates were not an option (no conclusions were made that would have required biological replicates)? How was this addressed with reviewers? Thank you for any insight.